Abstract 143P
Background
The combination of local thermal ablation with immune checkpoint inhibitors perioperatively for small hepatocellular carcinoma (HCC) is yet to be explored. The aim of this phase II trial was to evaluate the safety and tolerability of thermal ablation in combination with tislelizumab, an anti-PD-1 antibody, in patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A or B, and to make a preliminary evaluation of the efficacy of this treatment modality.
Methods
This phase II trial (NCT04652440) enrolled newly diagnosed and recurrent HCC patients with 1 or 2 lesions of 2-5 cm in size. This study included two stages. The first stage included 6 patients for dose-limited toxicity (DLT) observation. Only if DLT appeared in < 2 patients, the other 24 patients would be included. Enrolled patients received the first dose of tislelizumab intravenously within 1 day before percutaneous thermal ablation, followed by infusions every 3 weeks for totally 4 doses. The primary endpoints were safety and tolerability. Secondary endpoints included the rate of complete response by first ablation (CR1), local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival (DFS) and overall survival (OS) rates.
Results
No DLT occurred in the first 6 patients, and the study completed recruiting a total 30 subjects in July 2023. Twenty-six subjects had already finished their study treatment and were followed regularly. One patient withdrew her informed consent after completion of the ablation and the first dose of study medication. The other 3 were still on tislelizumab therapy. Until the time of data cut-off (July 30, 2023), the most common adverse events were increased alanine aminotransferase (N=15) and aspartate aminotransferase (N=19) on the first day after ablation. The majority recovered after supportive treatment. 10 patients experienced grade 1-2 immune-related adverse events (irAEs), the most common were rash (N=8), pruritus (N=5), and anorexia (N=4). No ≥3 grade irAEs occurred.
Conclusions
Thermal ablation combined with tislelizumab showed acceptable safety and tolerability with no unexpected SAEs observed. Results of efficacy will be disclosed in future.
Clinical trial identification
NCT04652440.
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract